SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Donadio JV Jr, Holley KE, Ferguson RH, Ilstrup DM. Treatment of diffuse proliferative lupus nephritis with prednisone and combined prednisone and cyclophosphamide. N Engl J Med 1978; 299: 11515.
  • 2
    Austin HA III, Klippel JH, Balow JE, le Riche NG, Steinberg AD, Plotz PH, et al. Therapy of lupus nephritis: controlled trial of prednisone and cytotoxic drugs. N Engl J Med 1986; 314: 6149.
  • 3
    Boumpas DT, Austin HA III, Vaughan EM, Klippel JH, Steinberg AD, Yarboro CH, et al. Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet 1992; 340: 7415.
  • 4
    Lewis EJ, Hunsicker LG, Lan SP, Rohde RD, Lachin JM. A controlled trial of plasmapheresis therapy in severe lupus nephritis. N Engl J Med 1992; 326: 13739.
  • 5
    Valeri A, Radhakrishnan J, Estes D, D'Agati V, Kopelman R, Pernis A, et al. Intravenous pulse cyclophosphamide treatment of severe lupus nephritis: a prospective five-year study. Clin Nephrol 1994; 42: 718.
  • 6
    Belmont HM, Storch M, Buyon J, Abramson S. New York University/Hospital for Joint Diseases experience with intravenous cyclophosphamide treatment: efficacy in steroid unresponsive lupus nephritis. Lupus 1995; 4: 1048.
  • 7
    Dooley MA, Hogan S, Jennette C, Falk R. Cyclophosphamide therapy for lupus nephritis: poor renal survival in black Americans. Kidney Int 1997; 51: 118895.
  • 8
    Gourley MF, Austin HA III, Scott D, Yarboro CH, Vaughan EM, Muir J, et al. Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis: a randomized, controlled trial. Ann Intern Med 1996; 125: 54957.
  • 9
    Lehman TJ, Onel K. Intermittent intravenous cyclophosphamide arrests progression of the renal chronicity index in childhood systemic lupus erythematosus. J Pediatr 2000; 136: 2437.
  • 10
    Berden JH. Lupus nephritis. Kidney Int 1997; 52: 53858.
  • 11
    Bakir AA, Levy PS, Dunea G. The prognosis of lupus nephritis in African-Americans: a retrospective analysis. Am J Kidney Dis 1994; 24: 15971.
  • 12
    Chan TM, Li FK, Wong RW, Wong KL, Chan KW, Cheng IK. Sequential therapy for diffuse proliferative and membranous lupus nephritis: cyclophosphamide and prednisolone followed by azathioprine and prednisolone. Nephron 1995; 71: 3217.
  • 13
    Ciruelo E, de la Cruz J, López I, Gómez-Reino JJ. Cumulative rate of relapse of lupus nephritis after successful treatment with cyclophosphamide. Arthritis Rheum 1996; 39: 202834.
  • 14
    Moroni G, Quaglini S, Maccario M, Banfi G, Ponticelli C. “Nephritic flares” are predictors of bad long-term renal outcome in lupus nephritis. Kidney Int 1996; 50: 204753.
  • 15
    Wagner-Weiner L, Magilavy DB, Emery HM. Flare of childhood lupus nephritis after discontinuing treatment with intravenous pulse cyclophosphamide [abstract]. Arthritis Rheum 1988; 31 Suppl 4: S117.
  • 16
    Ioannidis JPA, Boki KA, Katsorida ME, Drosos AA, Skopouli FN, Boletis JN, et al. Remission, relapse, and re-remission of proliferative lupus nephritis treated with cyclophosphamide. Kidney Int 2000; 57: 25864.
  • 17
    Ter Borg EJ, Horst G, Hummel EJ, Limburg PC, Kallenberg CGM. Measurement of increases in anti–double-stranded DNA antibody levels as a predictor of disease exacerbation in systemic lupus erythematosus: a long-term, prospective study. Arthritis Rheum 1990; 33: 63443.
  • 18
    Ricker DM, Hebert LA, Rohde R, Sedmak DD, Lewis EJ, Clough JD. Serum C3 levels are diagnostically more sensitive and specific for systemic lupus erythematosus activity than are serum C4 levels. The Lupus Nephritis Collaborative Study Group. Am J Kidney Dis 1991; 18: 67885.
  • 19
    Austin HA, Muenz LR, Joyce KM, Antonovych TT, Balow JE. Diffuse proliferative lupus nephritis: identification of specific pathologic features affecting renal outcome. Kidney Int 1984; 25: 68995.
  • 20
    Cox DR. Regression methods and life tables (with discussion). J R Stat Soc B 1972; 34: 187220.
  • 21
    Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 45781.
  • 22
    Welch TR, Brickman C, Bishof N, Maringhini S, Rutkowski M, Frenzke M, et al. The phenotype of SLE associated with complete deficiency of complement isotype C4A. J Clin Immunol 1998; 18: 4851.
  • 23
    Howard PF, Hochberg MC, Bias WB, Arnett FC Jr, McLean RH. Relationship between C4 null genes, HLA-D region antigens, and genetic susceptibility to systemic lupus erythematosus in Caucasian and black Americans. Am J Med 1986; 81: 18793.
  • 24
    Sullivan KE, Kim NA, Goldman D, Petri MA. C4A deficiency due to a 2 bp insertion is increased in patients with systemic lupus erythematosus. J Rheumatol 1999; 26: 21447.
  • 25
    Salmon JE, Millard S, Schachter LA, Arnett FC, Ginzler EM, Gourley MF, et al. Fcγ RIIA alleles are heritable risk factors for lupus nephritis in African Americans. J Clin Invest 1996; 97: 134854.
  • 26
    Freedman BI, Soucie JM, Stone SM, Pegram S. Familial clustering of end-stage renal disease in blacks with HIV-associated nephropathy. Am J Kidney Dis 1999; 34: 2548.
  • 27
    Freedman BI, Tuttle AB, Spray BJ. Familial predisposition to nephropathy in African-Americans with non-insulin-dependent diabetes mellitus. Am J Kidney Dis 1995; 25: 7103.
  • 28
    Freedman BI, Wilson CH, Spray BJ, Tuttle AB, Olorenshaw IM, Kammer GM. Familial clustering of end-stage renal disease in blacks with lupus nephritis. Am J Kidney Dis 1997; 29: 72932.
  • 29
    Freedman BI, Yu H, Spray BJ, Rich SS, Rothschild CB, Bowden DW. Genetic linkage analysis of growth factor loci and end-stage renal disease in African Americans. Kidney Int 1997; 51: 81925.
  • 30
    Austin HA, Boumpas DT, Vaughan EM, Balow JE. High-risk features of lupus nephritis: importance of race and clinical and histological factors in 166 patients. Nephrol Dial Transplant 1995; 10: 16208.